Post by Vested Finance

Can a weight loss drug treat Alzheimer's? Novo Nordisk is betting billions to find out. Their massive phase 3 trials (1,800 patients, 30 countries) wrap up this year, and the results could either: ✅ Unlock a $9.2 billion market and revive their beaten-down stock ❌ Prove that even promising science doesn't always translate to clinical success Early data shows 40-70% lower Alzheimer's rates among semaglutide users. But translating that into actual treatment efficacy? That's the gamble. We analyzed the entire situation, the science, the skeptics, and the market opportunity. Full breakdown in the article below. 👇